Your request to link to rcsb for Nuclear receptor ROR-gamma

• 3B0W: crystal structure of the orphan nuclear receptor ror(gamma)t ligand- binding domain in complex with digoxin (10.1074/JBC.M111.254003 )
• 3KYT: crystal structure of orphan nuclear receptor rorgamma in complex with natural ligand (10.1210/ME.2009-0507 )
• 3L0J: crystal structure of orphan nuclear receptor rorgamma in complex with natural ligand (10.1210/ME.2009-0507 )
• 3L0L: crystal structure of orphan nuclear receptor rorgamma in complex with natural ligand (10.1210/ME.2009-0507 )
• 4NB6: crystal structure of the ligand binding domain of rorc with t0901317 (10.1016/J.BMCL.2013.10.054 )
• 4NIE: crystal structure of the orphan nuclear receptor ror(gamma)t ligand- binding domain in complex with small molecule ligand (10.1021/ML4003875 )
• 4QM0: crystal structure of rorc in complex with a tertiary sulfonamide inverse agonist (10.1016/J.BMCL.2014.06.048 )
• 4S14: crystal structure of the orphan nuclear receptor rorgamma ligand- binding domain in complex with 4alpha-caboxyl, 4beta-methyl- zymosterol (4acd8) (10.1016/J.CMET.2015.01.004 )
• 4WLB: crystal structure of rorc in complex with a partial inverse agonist compound (10.1016/J.BMCL.2014.10.037 )
• 4WPF: crystal structure of rorc in complex with a phenyl sulfonamide agonist (10.1021/ML500420Y )
• 4WQP: crystal structure of rorc in complex with a benzyl sulfonamide inverse agonist (10.1021/ML500420Y )
• 4XT9: rorgamma (263-509) complexed with gsk2435341a and src2 (10.1016/J.BMC.2015.07.068 )
• 4YMQ: x-ray co-structure of nuclear receptor ror-gammat + src2 peptide with a benzothiadiazole dioxide inverse agonist (10.1016/J.BMCL.2015.03.042 )
• 4YPQ: crystal structure of the ror(gamma)t ligand binding domain in complex with 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1h-indazol-3-yl) benzoic acid (10.1038/NCOMMS9833 )
• 4ZJR: rorgamma in complex with inverse agonist 48 (10.1016/J.BMCL.2015.05.026 )
• 4ZJW: rorgamma in complex with inverse agonist 16 (10.1016/J.BMCL.2015.05.026 )
• 4ZOM: rorgamma in complex with inverse agonist 4j. (10.1016/J.BMCL.2015.05.028 )
• 5APH: ligand complex of rorg lbd (10.1002/CMDC.201500432 )
• 5APJ: ligand complex of rorg lbd (10.1002/CMDC.201500432 )
• 5APK: ligand complex of rorg lbd (10.1002/CMDC.201500432 )
• 5AYG: crystal structure of the human ror gamma ligand binding domain with 3g (10.1021/ACSMEDCHEMLETT.5B00253 )
• 5C4O: identification of a novel allosteric binding site for rorgt inhibitors (10.1038/NCOMMS9833 )
• 5C4S: identification of a novel allosteric binding site for rorgt inhibitors (10.1038/NCOMMS9833 )
• 5C4T: identification of a novel allosteric binding site for rorgt inhibitors (10.1038/NCOMMS9833 )
• 5C4U: identification of a novel allosteric binding site for rorgt inhibitors (10.1038/NCOMMS9833 )
• 5EJV: rory in complex with t090131718 and coactivator peptide ebi96 (10.1016/J.BMCL.2016.03.109 )
• 5ETH: rory in complex with inverse agonist 3. (10.1016/J.BMCL.2016.03.109 )
• 5G42: ligand complex of rorg lbd (10.1002/CMDC.201600242 )
• 5G43: ligand complex of rorg lbd (10.1002/CMDC.201600242 )
• 5G44: ligand complex of rorg lbd (10.1002/CMDC.201600242 )
• 5G45: ligand complex of rorg lbd (10.1002/CMDC.201600242 )
• 5G46: ligand complex of rorg lbd (10.1002/CMDC.201600242 )
• 5IXK: rorgamma in complex with inverse agonist bio399. (10.1186/S12900-016-0059-3 )
• 5IZ0: rorgamma in complex with agonist bio592 and coactivator ebi96 (10.1186/S12900-016-0059-3 )
• 5K38: crystal structure of retinoic acid receptor-related orphan receptor (ror) gamma ligand binding domain
• 5K3L: crystal structure of retinoic acid receptor-related orphan receptor (ror) gamma ligand binding domain complex with 444
• 5K3M: crystal structure of retinoic acid receptor-related orphan receptor (ror) gamma ligand binding domain complex with uua
• 5K3N: crystal structure of retinoic acid receptor-related orphan receptor (ror) gamma ligand binding domain complex with ml209
• 5K6E: crystal structure of retinoic acid receptor-related orphan receptor (ror) gamma ligand binding domain complex with sbi0654919
• 5K74: crystal structure of retinoic acid receptor-related orphan receptor (ror) gamma ligand binding domain complex with sbi0655870
• 5LWP: discovery of phenoxyindazoles and phenylthioindazoles as rorg inverse agonists (10.1016/J.BMCL.2016.10.023 )
• 5M96: synthesis and biological evaluation of new triazolo and imidazolopyridine rorgt inverse agonists (10.1002/CMDC.201600500 )
• 5NI5: ligand complex of rorg lbd (10.1021/ACS.JMEDCHEM.8B00783 )
• 5NI7: ligand complex of rorg lbd (10.1021/ACS.JMEDCHEM.8B00783 )
• 5NI8: ligand complex of rorg lbd (10.1021/ACS.JMEDCHEM.8B00783 )
• 5NIB: ligand complex of rorg lbd (10.1021/ACS.JMEDCHEM.8B00783 )
• 5NTI: structural states of rorgt: x-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds (10.1002/CMDC.201700278 )
• 5NTK: structural states of rorgt: x-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds (10.1002/CMDC.201700278 )
• 5NTN: structural states of rorgt: x-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds (10.1002/CMDC.201700278 )
• 5NTP: structural states of rorgt: x-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds (10.1002/CMDC.201700278 )
• 5NTQ: structural states of rorgt: x-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds (10.1002/CMDC.201700278 )
• 5NTW: structural states of rorgt: x-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds (10.1002/CMDC.201700278 )
• 5NU1: structural states of rorgt: x-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds (10.1002/CMDC.201700278 )
• 5UFO: structure of rorgt bound to (10.1016/J.BMCL.2017.02.044 )
• 5UFR: structure of rorgt bound to (10.1016/J.BMCL.2017.02.044 )
• 5UHI: structure of rorgt bound to (10.1016/J.BMCL.2017.02.044 )
• 5VB3: x-ray structure of nuclear receptor ror-gammat ligand binding domain + src2 peptide (10.1074/JBC.M117.789024 )
• 5VB5: x-ray co-structure of nuclear receptor ror-gammat ligand binding domain with an inverse agonist and src2 peptide (10.1074/JBC.M117.789024 )
• 5VB6: x-ray co-structure of nuclear receptor ror-gammat ligand binding domain with an inverse agonist and src2 peptide (10.1074/JBC.M117.789024 )
• 5VB7: x-ray co-structure of nuclear receptor ror-gammat ligand binding domain with an agonist and src2 peptide (10.1074/JBC.M117.789024 )
• 5VQK: x-ray co-structure of nuclear receptor ror-gammat ligand binding domain with a inverse agonist and src2 peptide
• 5VQL: x-ray co-structure of nuclear receptor ror-gammat ligand binding domain with a inverse agonist and src2 peptide
• 5W4R: structure of rorgt bound to a tertiary alcohol (10.1016/J.BMCL.2017.10.027 )
• 5W4V: structure of rorgt bound to a tertiary alcohol (10.1016/J.BMCL.2017.10.027 )
• 5X8Q: crystal structure of the mutant human ror gamma ligand binding domain with rockogenin. (10.1111/GTC.12494 )
• 5X8S: crystal structure of the mutant human ror gamma ligand binding domain with ursolic acid. (10.1111/GTC.12494 )
• 5X8U: crystal structure of the wild human ror gamma ligand binding domain. (10.1111/GTC.12494 )
• 5X8W: crystal structure of the mutant human ror gamma ligand binding domain. (10.1111/GTC.12494 )
• 5X8X: crystal structure of the mutant human ror gamma ligand binding domain with compound a. (10.1111/GTC.12494 )
• 5YP5: crystal structure of rorgamma complexed with src2 and compound 5d (10.1021/ACSMEDCHEMLETT.7B00476 )
• 5YP6: rorgamma (263-509) complexed with src2 and compound 6 (10.1021/ACSMEDCHEMLETT.7B00476 )
• 5ZA1: ligand complex of rorgt lbd (10.1016/J.BMCL.2018.09.032 )
• 6A22: ternary complex of human ror gamma ligand binding domain with compound t. (10.1038/S41598-018-35783-9 )
• 6B30: structure of rorgt in complex with a novel inverse agonist 1 (10.1016/J.BMC.2017.12.006 )
• 6B31: structure of rorgt in complex with a novel inverse agonist 2 (10.1016/J.BMC.2017.12.039 )
• 6B33: structure of rorgt in complex with a novel inverse agonist 3 (10.1002/CMDC.201900416 )
• 6BN6: identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as rorgt/rorc inverse agonists (10.1016/J.BMCL.2017.12.006 )
• 6BR2: structure of rorgt in complex with a novel isoquinoline inverse agonist. (10.1021/ACS.JMEDCHEM.8B00061 )
• 6BR3: structure of rorgt in complex with a novel inverse agonist tak-828. (10.1021/ACS.JMEDCHEM.8B00061 )
• 6CN5: human retenoid-related orphan receptor-gamma ligand- binding domain in complex with indole ligand cp9b in inverse agonist conformation (10.1021/ACS.JMEDCHEM.8B00392 )
• 6CN6: rorc2 lbd complexed with compound 34 (10.1021/ACS.JMEDCHEM.8B00392 )
• 6CVH: identification and biological evaluation of thiazole-based inverse agonists of rorgt (10.1016/J.BMCL.2018.03.093 )
• 6E3E: structure of rorgt in complex with a novel inverse agonist. (10.1021/ACS.JMEDCHEM.8B01181 )
• 6E3G: structure of rorgt in complex with a novel agonist. (10.1021/ACS.JMEDCHEM.8B01181 )
• 6ESN: ligand complex of rorg lbd (10.1021/ACS.JMEDCHEM.8B00783 )
• 6FGQ: ligand complex of rorg lbd (10.1021/ACS.JMEDCHEM.8B00783 )
• 6FZU: rorgt (264-518;c455s) in complex with the fragment ("cpd-1") and rip140 peptide at 1.80a (10.1021/ACS.JMEDCHEM.8B00529 )
• 6G05: rorgt (264-518;c455s) in complex with inverse agonist "cpd-2" and rip140 peptide at 1.90a (10.1021/ACS.JMEDCHEM.8B00529 )
• 6G07: rorgt (264-518;c455s) in complex with inverse agonist "cpd-9" and rip140 peptide at 1.66a (10.1021/ACS.JMEDCHEM.8B00529 )
• 6IVX: discovery of the second generation ror gamma inhibitors composed of an azole scaffold. (10.1021/ACS.JMEDCHEM.8B01567 )
• 6J1L: crystal structure analysis of the ror gamma(c455e) 28-aug-19 6j1l 1 title (10.1021/ACS.JMEDCHEM.9B00327 )
• 6J3N: rorgammat lbd complexed with ursonic acid and src2.2
• 6LO9: crystal structure of rorgammat with ligand c46d bound
• 6LOA: crystal structure of rorgammat with ligand c46d bound
• 6LOB: crystal structure of rorgammat with ligand c46d bound
• 6LOC: crystal structure of rorgammat with ligand c46d bound
• 6NAD: identification and biological evaluation of tertiary alcohol-based inverse agonists of rorgt (10.1016/J.BMCL.2019.04.021 )
• 6NWS: rorgamma ligand binding domain (10.7554/ELIFE.47172 )
• 6NWT: rorgamma ligand binding domain (10.7554/ELIFE.47172 )
• 6NWU: rorgamma ligand binding domain (10.7554/ELIFE.47172 )
• 6O3Z: crystal structure of rorgt with 3-cyano-n-(3-{[(3s)-4- (cyclopentanecarbonyl)-3-methylpiperazin-1-yl]methyl}-5-fluoro-2- methylphenyl)benzamide (compound 1) (10.1021/ACSMEDCHEMLETT.9B00649 )
• 6O98: crystal structure of rar-related orphan receptor c in complex with a phenyl (3-phenylpyrrolidin-3-yl)sulfone inhibitor (10.1021/ACSMEDCHEMLETT.9B00010 )
• 6P9F: crystal structure of rar-related orphan receptor c (nhis-rorgt(244- 487)-l6-src1(678-692)) in complex with a phenyl (3-phenylpyrrolidin- 3-yl)sulfone inhibitor (10.1016/J.BMCL.2019.06.036 )
• 6Q2W: crystal structure of human ror gamma lbd in complex with a quinoline sulfonamide inverse agonist (10.1016/J.BMCL.2019.05.015 )
• 6Q6M: rorcvar2 (rorgt, 264-499) in complex with compound 1: identification of n-aryl imidazoles as potent and selective rorgt inhibitors (10.1021/ACS.JMEDCHEM.9B01291 )
• 6Q6O: rorcvar2 (rorgt, 264-499) in complex with compound 2 at 2.3a: identification of n-aryl imidazoles as potent and selective rorgt inhibitors (10.1021/ACS.JMEDCHEM.9B01291 )
• 6Q7A: rorcvar2 (rorgt, 264-499) in complex with compound 4 at 2.2a: identification of n-aryl imidazoles as potent and selective rorgt inhibitors (10.1021/ACS.JMEDCHEM.9B01291 )
• 6Q7H: rorcvar2 (rorgt, 264-499) in complex with compound 9 at 2.3a: identification of n-aryl imidazoles as potent and selective rorgt inhibitors (10.1021/ACS.JMEDCHEM.9B01291 )
• 6R7A: ligand complex of rorg lbd (10.1021/ACSMEDCHEMLETT.9B00158 )
• 6R7J: ligand complex of rorg lbd (10.1021/ACSMEDCHEMLETT.9B00158 )
• 6R7K: ligand complex of rorg lbd (10.1021/ACSMEDCHEMLETT.9B00158 )
• 6SAL: ror(gamma)t ligand binding domain in complex with allosteric ligand fm26 (10.1021/ACS.JMEDCHEM.9B01372 )
• 6SLZ: crystal structure of human ror gamma lbd in complex with a (quinolinoxymethyl)benzamide inverse agonist
• 6T4G: ror(gamma)t ligand binding domain in complex with cholesterol and allosteric ligand fm26 (10.1073/PNAS.2021287118 )
• 6T4I: ror(gamma)t ligand binding domain in complex with cholesterol and allosteric ligand mrl871 (10.1073/PNAS.2021287118 )
• 6T4J: ror(gamma)t ligand binding domain in complex with desmosterol and allosteric ligand fm26 (10.1073/PNAS.2021287118 )
• 6T4K: ror(gamma)t ligand binding domain in complex with desmosterol and allosteric ligand mrl871 (10.1073/PNAS.2021287118 )
• 6T4T: ror(gamma)t ligand binding domain in complex with 20-alpha- hydroxycholesterol and allosteric ligand fm26 (10.1073/PNAS.2021287118 )
• 6T4U: ror(gamma)t ligand binding domain in complex with 20-alpha- hydroxycholesterol and allosteric ligand mrl871 (10.1073/PNAS.2021287118 )
• 6T4W: ror(gamma)t ligand binding domain in complex with 20-alpha- hydroxycholesterol and allosteric ligand glenmark (10.1073/PNAS.2021287118 )
• 6T4X: ror(gamma)t ligand binding domain in complex with 25- hydroxycholesterol and allosteric ligand fm26 (10.1073/PNAS.2021287118 )
• 6T4Y: ror(gamma)t ligand binding domain in complex with 25- hydroxycholesterol and allosteric ligand mrl871 (10.1073/PNAS.2021287118 )
• 6T50: ror(gamma)t ligand binding domain in complex with 25- hydroxycholesterol and allosteric ligand glenmark (10.1073/PNAS.2021287118 )
• 6TLM: ror(gamma)t ligand binding domain in complex with allosteric ligand compound 13 (glenmark) (10.1002/CMDC.202000044 )
• 6TLQ: ror(gamma)t ligand binding domain in complex with cholesterol and allosteric ligand glenmark (10.1073/PNAS.2021287118 )
• 6TLT: ror(gamma)t ligand binding domain in complex with desmosterol and allosteric ligand glenmark (10.1073/PNAS.2021287118 )
• 6U25: crystal structure of rar-related orphan receptor c (nhis- rorgt(244- 487)-l6-src1(678-692)) in complex with a tricyclic inverse agonist (10.1021/ACS.JMEDCHEM.9B01369 )
• 6UCG: retinoic acid receptor-related orphan receptor (ror) gamma in complex with allosteric compound 28 (10.1021/ACSMEDCHEMLETT.9B00431 )
• 6VQF: crystal structure of rar-related orphan receptor c (nhis-rorgt(244- 487)-l6-src1(678-692)) in complex with an inverse agonist (10.1021/ACSMEDCHEMLETT.0C00063 )
• 6VSW: optimization and biological evaluation of thiazole-bis-amide inverse agonists of rorgt (10.1016/J.BMCL.2020.127205 )
• 6W9H: substituted benzyloxytricyclic compounds as retinoic acid-related orphan receptor gamma t agonists (10.1016/J.BMCL.2020.127204 )
• 6W9I: substituted benzyloxytricyclic compounds as retinoic acid-related orphan receptor gamma t agonists (10.1016/J.BMCL.2020.127204 )
• 6XAE: substituted benzyloxytricyclic compounds as retinoic acid-related orphan receptor gamma t agonists (10.1016/J.BMCL.2020.127204 )
• 6XFV: crystal structure of rar-related orphan receptor c in complex with a novel inverse agonist (10.1016/J.BMCL.2020.127392 )
• 7E3M: rorgamma lbd complexed with panaxatriol and src2.2
• 7JH2: crystal structure of rar-related orphan receptor c in complex with a potent, selective and orally bioavailable ror-gamma-t inverse agonist (10.1016/J.BMCL.2020.127441 )
• 7JTM: crystal structure of rar-related orphan receptor c (nhis-rorgt(244- 487)-l6-src1(6t78-692) in complex with a tricyclic sulfone rorgt inverse agonist (10.1016/J.BMCL.2020.127521 )
• 7JTW: crystal structure of rorgt with compound (4r)-6-[(2,5-dichloro-3- {[(2r,4r)-1-(cyclopentanecarbonyl)-2-methylpiperidin-4- yl]oxy}phenyl)amino]-6-oxo-4-phenylhexanoic acid (10.1016/J.BMCL.2021.127786 )
• 7JYM: crystal structure of rar-related orphan receptor c (nhis-rorgt(244- 487)-l6-src1(678-692)) in complex with a tricyclic sulfone inverse agonist (10.1021/ACSMEDCHEMLETT.0C00496 )
• 7KCO: ror gamma in complex with scr2 and compound 3 (10.1021/ACS.JMEDCHEM.0C01918 )
• 7KQJ: crystal structure of rar-related orphan receptor c (nhis-rorgt(244- 487)-l6-src1(678-692) in complex with a novel tricyclic-carbocylic rorgt inverse agonist (10.1021/ACS.JMEDCHEM.0C01992 )
• 7KXD: crystal structure of rar-related orphan receptor c (nhis-rorgt(244- 487)-l6-src1(678-692)) in complex with {3,5-dichloro-4-[4-methoxy-3- (propan-2-yl)phenoxy]phenyl}methanol (10.1016/J.BMCL.2021.127778 )
• 7KXE: crystal structure of rar-related orphan receptor c (nhis-rorgt(244- 487)-l6-src1(678-692)) in complex with {3,5-dichloro-4-[4-methoxy-3- (propan-2-yl)phenoxy]phenyl}methanol (10.1016/J.BMCL.2021.127778 )
• 7KXF: crystal structure of rar-related orphan receptor c (nhis-rorgt(244- 487)-l6-src1(678-692)) in complex with {3,5-dichloro-4-[4-methoxy-3- (propan-2-yl)phenoxy]phenyl}methanol (10.1016/J.BMCL.2021.127778 )
• 7LUK: crystal structure of rar-related orphan receptor c (nhis-rorgt(244- 487)-l6-src1(678-692) in complex with an azatricyclic rorgt inverse agonist (10.1021/ACSMEDCHEMLETT.1C00112 )
• 7NEC: ror(gamma)t ligand binding domain in complex with allosteric ligand fm217 (10.1021/ACS.JMEDCHEM.1C00475 )
• 7NP5: ror(gamma)t ligand binding domain in complex with allosteric ligand fm216 (10.1021/ACS.JMEDCHEM.1C00475 )
• 7NP6: ror(gamma)t ligand binding domain in complex with allosteric ligand fm257 (10.1021/ACS.JMEDCHEM.1C00475 )
• 7NPC: ror(gamma)t ligand binding domain in complex with allosteric ligand fm156 (10.1021/ACS.JMEDCHEM.1C00475 )
• 7OFI: ligand complex of rorg lbd (10.1021/ACS.JMEDCHEM.1C01197 )
• 7OFK: ligand complex of rorg lbd (10.1021/ACS.JMEDCHEM.1C01197 )